Henry Schein, Inc. (HSIC) Given Hold Rating at Credit Suisse Group
Credit Suisse Group reissued their hold rating on shares of Henry Schein, Inc. (NASDAQ:HSIC) in a research report report published on Tuesday morning. The brokerage currently has a $175.00 target price on the stock.
Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Henry Schein from a hold rating to a buy rating and set a $206.00 target price for the company in a research note on Friday, June 16th. Northcoast Research upgraded Henry Schein from a neutral rating to a buy rating and set a $218.00 target price for the company in a research note on Monday, August 7th. Stifel Nicolaus lifted their price target on Henry Schein from $174.00 to $178.00 and gave the stock a hold rating in a research note on Wednesday, May 10th. Finally, Jefferies Group LLC reiterated a hold rating and issued a $177.00 price target on shares of Henry Schein in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $186.50.
Shares of Henry Schein (NASDAQ HSIC) traded up 0.42% during midday trading on Tuesday, reaching $169.14. 455,785 shares of the company’s stock traded hands. The stock has a market cap of $13.37 billion, a P/E ratio of 24.72 and a beta of 1.09. Henry Schein has a 52-week low of $146.23 and a 52-week high of $186.99. The stock has a 50-day moving average price of $177.99 and a 200-day moving average price of $175.84. Shares of Henry Schein are scheduled to split on the morning of Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly created shares will be distributed to shareholders after the market closes on Thursday, September 14th.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.02. The company had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a return on equity of 19.10% and a net margin of 4.74%. The company’s revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm earned $1.64 earnings per share. Analysts forecast that Henry Schein will post $7.27 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/henry-schein-inc-hsic-given-hold-rating-at-credit-suisse-group/1532368.html.
Institutional investors have recently modified their holdings of the company. YorkBridge Wealth Partners LLC boosted its position in shares of Henry Schein by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after buying an additional 28 shares in the last quarter. Sun Life Financial INC boosted its position in shares of Henry Schein by 8,185.7% in the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after buying an additional 573 shares in the last quarter. SpiderRock Advisors LLC acquired a new position in shares of Henry Schein during the first quarter worth about $102,000. Lee Financial Co acquired a new position in shares of Henry Schein during the second quarter worth about $161,000. Finally, JNBA Financial Advisors acquired a new position in shares of Henry Schein during the first quarter worth about $170,000. 89.08% of the stock is currently owned by hedge funds and other institutional investors.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.